A Study of Sodium Oligomannate (GV-971) in Participants With Mild to Moderate Alzheimer's Disease

  • End date
    Oct 2, 2026
  • participants needed
  • sponsor
    Shanghai Greenvalley Pharmaceutical Co., Ltd.
Updated on 2 July 2021
mini-mental state examination
alzheimer's disease


The purpose of this study is to evaluate the safety, tolerability and efficacy of GV-971 in mild to moderate Alzheimer's disease.

Condition Dementia, Alzheimer's Disease, alzheimer, dementia alzheimer's type
Treatment Placebo, GV-971
Clinical Study IdentifierNCT04520412
SponsorShanghai Greenvalley Pharmaceutical Co., Ltd.
Last Modified on2 July 2021


Yes No Not Sure

Inclusion Criteria

Mild to moderate AD per NIA-AA
History of cognitive and functional decline over at least 1 year
MMSE scores between 11 and 24 (inclusive) at baseline
Brain MRI scan show the highest possibility of AD
Have a study partner/caregiver

Exclusion Criteria

Diagnosis of a dementia-related central nervous system disease other than AD
Major structural brain disease as judged by MRI
A resting heart rate of < 50 beats per minute (bpm) after 5 minutes of rest in sitting or supine position
Major medical illness or unstable medical condition within 6 months of screening
Concomitant use of AChEIs and/or memantine within 30 days before first MMSE score, and during the study
Inadequate hepatic function
Inadequate organ and marrow function
ECG clinically significant abnormalities
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Preferred Language
Other Language
Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note